3Jemal A,Siegel R,Ward E,et al. Cancer statistics,2008[J]. CA Cancer J Clin,2008,58(2) :71-96.
4Sung JY, Lau JY, Goh KL, et al. Increasing incidence of colorectal cancer in Asia: Implications for screening. For the Asia Pacific Working Group on Colorectal Cancer[J]. Lancet Oncology,2005,6(11) :871-876.
5Bresalier RS, Sandier RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J]. N Engl J Med,2005,352(11) :1092- 1020.
6Poynter JN,Gruber SB,Higgins PD,et al. Statins and the risk of colorectal cancer[J]. N Engl J Med, 2005,352 (21) : 2184-2192.
7Cipollone F, Fazia M, Iezzi A, et al. Suppression of the functionally coupled cyclooxygenase-2 / prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans[J]. Circulation, 2003,107 (11): 1479- 1485.
8Habib A, Shamseddeen I, Nasrallah MS, et al. Modulation of COX-2 expression by statins in human monocytic cells[J]. FASEB J, 2007,21 (8) : 1665-1674.
9Konturek PC, Burnat G, Hahn EG. Inhibition of Barret's adenocareinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins[J]-. J Physiol Pharmacol, 2007,58( Suppl 3):141-148.
10Blank N, Schiller M, Krienke S, et al. Atorvastatin inhibits T cell activation through 3-Hydroxy-3-methylglutaryl coenzyme A reductase without decreasing cholesterol synthesis [J]. J Immunology, 2007,179 (6) :3613-3621.
